Placebo vaccine
Placebo vaccine is a biological therapy with 29 clinical trials. Currently 2 active trials ongoing. Historical success rate of 95.5%.
Success Metrics
Based on 21 completed trials
Phase Distribution
Phase Distribution
17
Early Stage
5
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
87.5%
21 of 24 finished
12.5%
3 ended early
2
trials recruiting
29
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions
Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults
Long Term Effects of BCG Vaccination on Infectious and Immune Mediated Diseases
Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis
Clinical Trials (29)
Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions
Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults
Long Term Effects of BCG Vaccination on Infectious and Immune Mediated Diseases
Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis
BCG Vaccine for Health Care Workers as Defense Against COVID 19
Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC
GVAX vs. Placebo for MDS/AML After Allo HSCT
Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation
Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women
Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda
Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Probiotic and Influenza Vaccination to Reducing Influenza-like Illness Incident in Elderly
Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years Old
Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults
Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart
Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 29